4-氯咪唑 | 15965-31-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 4-氯咪唑
• 中文别名: 2-正丁基-4-氯-5-甲酰基咪唑
• 英文名称: 4-chloro-1H-imidazole
• 英文别名: 4-chloroimidazole；4-Chlorimidazol；5-chloro-1H-imidazole
• CAS: 15965-31-8
• 化学式: C₃H₃ClN₂
• mdl: MFCD09033087
• 分子量: 102.523
• InChiKey: BQRBAXFOPZRMCU-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120°C
• 沸点：
  295.9±13.0 °C(Predicted)
• 密度：
  1.405
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloroimidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloroimidazole
CAS number: 15965-31-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H3ClN2
Molecular weight: 102.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  喹啉 、 4-氯咪唑 在 copper diacetate 、 potassium carbonate 、 Selectfluor 作用下， 以 硝基甲烷 为溶剂， 反应 3.0h， 以74%的产率得到2-(4-Chloroimidazol-1-yl)quinoline
  参考文献：
  名称：

  喹啉衍生物高区域选择性胺化新方法

  摘要：

  本发明属于有机合成化学技术领域，发明了一种金属盐催化喹啉衍生物与多种氮源生成2?胺基喹啉衍生物的新方法。本发明克服了目前已经报道的喹啉胺化需要提前活化的卤代喹啉或者氧化喹啉作为反应前体的限制，高区域选择性的实现了喹啉C2位的胺化反应。本发明所实现的胺化反应具有步骤简洁，操作简单，原料、试剂和催化剂易得等特点，适用于合成各种2?胺基喹啉衍生物，并且适用于大规模的工业生产。

  公开号：

  CN105753838A
• 作为产物：
  描述：

  咪唑 在 N-氯代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 反应 8.17h， 以79%的产率得到4-氯咪唑
  参考文献：
  名称：

  铜锰尖晶石氧化物催化苯酚和N-杂芳烃的区域选择性卤代反应

  摘要：

  已经开发出一种新颖的，简单的，温和的化学和区域选择性方法，使用Cu-Mn尖晶石氧化物作为催化剂，N-卤代琥珀酰亚胺作为卤化剂来卤化苯酚。在铜锰尖晶石氧化物B的存在，无论是吸电子和给电子基团的酚类轴承都给单卤代的产品良好的与最高优异的产率对位-选择性。该段取代酚给卤代的产品，良好的收益率和邻-选择性。ñ-诸如芳族吲哚和咪唑的杂芳烃也具有高选择性的单卤代产物。与铜催化的卤化不同，本方法对于带有吸电子基团的酚能很好地工作，并具有相对更好的产率和选择性。Cu-Mn尖晶石催化剂坚固耐用，可在优化条件下重复使用3次，而不会损失任何催化活性。非酚类没有经历这种转变。

  DOI：

  10.1021/jo300731z

文献信息

• [EN] SUBSTITUTED OXOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2017005725A1

  公开（公告）日：2017-01-12

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and o edemas, and also ophthalmic disorders.

  这项发明涉及替代氧吡啶衍生物及其制备方法，以及它们用于制备治疗和/或预防疾病的药物，特别是心血管疾病，最好是血栓性或血栓栓塞性疾病，以及水肿和眼科疾病。
• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
  申请人：FORUM Pharmaceuticals Inc.

  公开号：US20170044182A1

  公开（公告）日：2017-02-16

  The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

  本公开涉及融合吗啉吡嘧啶类化合物，包括有效量的融合吗啉吡嘧啶类化合物的药物组合物，以及在治疗神经退行性疾病中使用融合吗啉吡嘧啶类化合物的方法，包括向需要的受试者施用有效量的融合吗啉吡嘧啶类化合物。
• [EN] OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS OXADIAZINE ET LEURS MÉTHODES D'UTILISATION
  申请人：FORUM PHARMCEUTICALS INC

  公开号：WO2016201168A1

  公开（公告）日：2016-12-15

  The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

  本公开涉及恶二嗪化合物，包含有效量的恶二嗪化合物的药物组合物，以及使用恶二嗪化合物治疗神经退行性疾病的方法，包括向需要其的受试者施用有效量的恶二嗪化合物。
• 取代嘧啶脲类化合物及其用途
  申请人：华东理工大学

  公开号：CN105418592B

  公开（公告）日：2018-02-16

  本发明涉及一种取代嘧啶脲类化合物及其用途。所述取代嘧啶脲类化合物为式I所示化合物(具体结构请见说明书或权利要求书)、或其立体异构体或药学上可接受的盐。体外活性测试表明：本发明公开的取代嘧啶脲类化合物具有胆碱酯酶抑制活性、螯合金属离子、抑制金属离子诱导的自由基产生和抑制金属离子诱导的Aβ聚集等性能。因此，本发明提供的取代嘧啶脲类化合物有望被用于制备治疗和/或预防阿尔茨海默病药物。